AR050098A1 - USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY - Google Patents

USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY

Info

Publication number
AR050098A1
AR050098A1 ARP050103247A AR050098A1 AR 050098 A1 AR050098 A1 AR 050098A1 AR P050103247 A ARP050103247 A AR P050103247A AR 050098 A1 AR050098 A1 AR 050098A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
heterocyclyl
azydyl
aryl
group
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Thomas Stoehr
Christine Rauschkolb-Loeffler
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Priority to ARP050103247 priority Critical patent/AR050098A1/en
Publication of AR050098A1 publication Critical patent/AR050098A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Uso de un compuesto que tiene la formula (1), donde R es hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, arilo, aril(alquilo inferior), heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, cicloalquilo inferior o (cicloalquil inferior)alquilo inferior, y R está no sustituido o está sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; R1 es hidrogeno o alquilo inferior, alquenilo inferior, alquinilo inferior, aril(alquilo inferior), arilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, heterociclilo, cicloalquilo inferior, (cicloalquil inferior)alquilo inferior, cada uno no sustituido o sustituido con al menos un grupo dador de electrones y/o al menos un grupo aceptor de electrones; R2 y R3 son independientemente hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, aril(alquilo inferior), arilo, halo, heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, cicloalquilo inferior, (cicloalquil inferior)alquilo inferior o Z-Y, donde R2 y R3 pueden estar no sustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; y donde en R2 y R3 heterociclilo es furilo, tienilo, pirazolilo, pirrolilo, metilpirrolilo, imidazolilo, indolilo, triazolilo, oxazolilo, isotiazolilo, isoxazolilo, piperidilo, pirrolinilo, piperazinilo, quinolilo, triazolilo, tetrazolilo, isoquinolilo, benzofurilo, benzotienilo, morfolinilo, benzoxazolilo, tetrahidrofurilo, piranilo, indazolilo, purinilo, indolinilo, pirazolindinilo, imidazolinilo, imidazolindinilo, pirrolidinilo, furazanilo, N-metilindolilo, metilfurilo, piridazinilo, pirimidinilo, pirazinilo, piridilo, epoxi, aziridino, oxetanilo, azetidinilo, o, cuando N está presente en el heterociclilo, un N-oxido de los mismos; Z es O, S, S(O)a, NR4, NR6' o PR4 o un enlace químico; Y es hidrogeno, alquilo inferior, arilo, aril(alquilo inferior); alquenilo inferior, alquinilo inferior, halo, heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo e Y puede estar no sustituido o sustituido con al menos un grupo dador de electrones y/o al menos un grupo aceptor de electrones, donde heterociclilo tiene el mismo significado como R2 o R3 y con la condicion de que cuando Y es halo, entonces Z es un enlace químico; o Z e Y tomados conjuntamente como ZY son NR4NR5R7, NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR4R7, NR4SR7, SPR4R5, PR4SR7, NR4PR5R6, PR4NR5R7 o N+R5R6R7, o una formula (2); R6' es hidrogeno, alquilo inferior, alquenilo inferior o alquinilo inferior que pueden estar no sustituidos o sustituidos con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; R4, R5 y R6 son independientemente hidrogeno, alquilo inferior, arilo, aril(alquil inferior), alquenilo inferior o alquinilo inferior, donde R4, R5 y R6 independientemente pueden estar no sustituidos o sustituidos con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; y R7 es R6 o COOR8 o COR8, pudiendo R7 estar no sustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; R8 es hidrogeno o alquilo inferior, o aril(alquilo inferior), y el grupo arilo o alquilo puede estar no sustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo dador de electrones; y n es 1-4; y a es 1-3; o de una sal farmacéuticamente aceptable del mismo, caracterizado, porque dicho uso es para la preparacion de una composicion farmacéutica util para la prevencion, el alivio y/o el tratamiento de dolor trigeminal neuropático.Claim 1: Use of a compound having the formula (1), wherein R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl , lower cycloalkyl or (lower cycloalkyl) lower alkyl, and R is unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R1 is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl, heterocyclyl, lower cycloalkyl, (lower cycloalkyl) lower alkyl, each unsubstituted or substituted with at least one electron donor group and / or at least one electron acceptor group; R2 and R3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, halo, heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl, lower cycloalkyl, (lower cycloalkyl) lower alkyl or ZY, where R2 and R3 may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and where R2 and R3 heterocyclyl is furyl, thienyl, pyrazolyl, pyrrolyl, methylpyrrolyl, imidazolyl, indolyl, triazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolinyl, pyrazolindinyl, imidazolinyl, imidazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, azyridyl, azydyl, azetyl, azydyl, azethyl, azethyl, azethyl, ethyloid, azydyl, azydyl, ethyloid, azydyl, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloxy, nyl, ethyloxyl, ethyloxy, ethyloxy, ethyloxyl, azytyl, ethyloxy, ethyloxy, ethyloxy, azexyl, ethyloxyl, ethyloxy, ethyloxy, ethoxy; in the heterocyclyl, an N-oxide thereof; Z is O, S, S (O) a, NR4, NR6 'or PR4 or a chemical bond; Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl); lower alkenyl, lower alkynyl, halo, heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl and Y may be unsubstituted or substituted with at least one electron donor group and / or at least one electron acceptor group, where heterocyclyl it has the same meaning as R2 or R3 and with the proviso that when Y is halo, then Z is a chemical bond; or Z and Y taken together as ZY are NR4NR5R7, NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR4R7, NR4SR7, SPR4R5, PR4SR7, NR4PR5R6, PR4NR5R7 or N + R5R6R7, or a formula (2); R6 'is hydrogen, lower alkyl, lower alkenyl or lower alkynyl which may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R4, R5 and R6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl or lower alkynyl, where R4, R5 and R6 can independently be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and R7 is R6 or COOR8 or COR8, R7 being able to be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and n is 1-4; and a is 1-3; or of a pharmaceutically acceptable salt thereof, characterized in that said use is for the preparation of a pharmaceutical composition useful for the prevention, relief and / or treatment of neuropathic trigeminal pain.

ARP050103247 2005-08-04 2005-08-04 USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY AR050098A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP050103247 AR050098A1 (en) 2005-08-04 2005-08-04 USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP050103247 AR050098A1 (en) 2005-08-04 2005-08-04 USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY

Publications (1)

Publication Number Publication Date
AR050098A1 true AR050098A1 (en) 2006-09-27

Family

ID=37075364

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103247 AR050098A1 (en) 2005-08-04 2005-08-04 USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY

Country Status (1)

Country Link
AR (1) AR050098A1 (en)

Similar Documents

Publication Publication Date Title
AR049940A1 (en) USE OF PEPTIDIC COMPOUNDS TO TREAT ESSENTIAL TREMOR AND OTHER TREMOR SYNDROMES
AR056467A1 (en) USE OF PEPTIDE COMPOUNDS TO TREAT MUSCLE PAIN
AR061475A1 (en) PEPTIDIC COMPOUNDS TO TREAT STATUS EPILEPTICUS REFRACTORY
AR061743A1 (en) PEPTIDIC COMPOUNDS FOR THE TREATMENT OF HYPEREXCITABILITY DISORDERS AND ASSOCIATED DISORDERS WITH IRON CHANNEL DYSFUNCTION
AR050612A1 (en) NEW USE OF PEPTIDE COMPOUNDS TO TREAT PAIN FOR BONE CANCER, PAIN INDUCED BY CHEMOTHERAPY AND NUCLEOSIDS AND PHARMACEUTICAL COMPOSITION
AR061476A1 (en) PHARMACEUTICAL COMPOSITION WITH SYNERGIC ANTI-CONVULSIVE EFFECT
AR094277A1 (en) FUMARATE DERIVATIVES REPLACED WITH DEUTERIO
ATE476971T1 (en) ANTICONVULSIVALS CONTAINING AMINO ACID FOR THE TREATMENT OF OCD
Leclercq et al. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model
DE602007010781D1 (en) N- (PHENYLMETHYL) -2- (1H-PYRAZOL-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODE GENERATION
AR107927A1 (en) PIRROLIDINE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BR112015009850A2 (en) heteroaryl substituted pyridyl compounds useful as kinase modulators
JP2008501760A5 (en)
BR9714967A (en) Enhanced pharmaceutical compositions
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
TR200103351T2 (en) New pharmaceutical combinations for nos inhibitors.
AR050098A1 (en) USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN TRIGEMINAL NEURALGY
EA201690626A1 (en) NEW COMPOSITION OF HONADOTROPINS
AR050096A1 (en) USE OF PEPTIDIC COMPOUNDS TO TREAT DYSKINESIA
NZ719465A (en) Quinoline derivatives as bromodomain inhibitors
AR050097A1 (en) USE OF PEPTIDIC COMPOUNDS TO TREAT PAIN IN PAINFUL DIABETIC NEUROPATHY
AR050196A1 (en) USE OF PEPTIDIC COMPOUNDS TO TREAT AMIOTROPHIC LATERAL SCLEROSIS
AR111422A1 (en) N- (4-PIRIDIL) NICOTINAMIDE OR SALT OF THE SAME COMPOUNDS
AR050099A1 (en) USE OF PEPTIDIC COMPOUNDS FOR PROFILAXIS AND THE TREATMENT OF CHRONIC HEADACHE
CO5170469A1 (en) A PROCESS FOR THE SYNTHESIS OF FINALLY DIVIDED ANTIPERSPIRANT SUSPENTIONS